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The current pharmacopeia to treat the lethal human and animal diseases caused by the protozoan para-
site Trypanosoma brucei remains limited. The parasite’s ability to undergo antigenic variation represents a
considerable barrier to vaccine development, making the identiﬁcation of new drug targets extremely
important. Recent studies have demonstrated that fatty acid synthesis is important for growth and viru-
lence of Trypanosoma brucei brucei, suggesting this pathway may have therapeutic potential. The ﬁrst
committed step of fatty acid synthesis is catalyzed by acetyl-CoA carboxylase (ACC), which is a known
target of ()-epigallocatechin-3-gallate (EGCG), an active polyphenol compound found in green tea.
EGCG exerts its effects on ACC through activation of AMP-dependent protein kinase, which phosphory-
lates and inhibits ACC. We found that EGCG inhibited TbACC activity with an EC50 of 37 lM and
55 lM for bloodstream form and procyclic form lysates, respectively. Treatment with 100 lM EGCG
induced a 4.7- and 1.7- fold increase in TbACC phosphorylation in bloodstream form and procyclic
lysates. EGCG also inhibited the growth of bloodstream and procyclic parasites in culture, with a 48 h
EC50 of 33 lM and 27 lM, respectively, which is greater than the EGCG plasma levels typically achievable
in humans through oral dosing. Daily intraperitoneal administration of EGCG did not reduce the virulence
of an acute mouse model of T. b. brucei infection. These data suggest a reduced potential for EGCG to treat
T. brucei infections, but suggest that EGCG may prove to be useful as a tool to probe ACC regulation.
 2012 Australian Society for Parasitology Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
The protozoan parasite Trypanosoma brucei (sub-species gamb-
iense and rhodesiense) is the causative agent of African sleeping
sickness, a fatal human disease that ranges across sub-Saharan
Africa. In addition to causing substantial morbidity and mortality
in humans, a third sub-species, Trypanosoma brucei brucei is
responsible for causing nagana, a livestock disease that results in
wasting and death. Nagana imposes a tremendous economic bur-Published by Elsevier Ltd.
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Open accden on the region, causing 4.5 billion dollars in economic losses
each year (FAO, 2007). Vaccine development is confounded by
the parasite’s ability to switch its surface coat through antigenic
variation (Horn and McCulloch, 2010). Chemotherapeutics are re-
lied upon to battle the disease, yet currently approved drugs cause
undesirable side effects, are subject to failure, and can be too
expensive for citizens of economically depressed regions (Castillo
et al., 2010). To meet this urgent need, investigation of existing
compounds are an important avenue to identify potential new
drugs that are effective, safe, and economical.
Green tea is amongst the most widely consumed beverages
worldwide and is often touted for its wealth of medicinal effects
(Moon et al., 2007; Khan and Mukhtar, 2008; Thielecke and Bosch-
mann, 2009; Ahmed, 2010). The best-studied active components of
green tea are the catechins, of which ()-epigallocatechin-3-gallate
(EGCG) is one of the most abundant (Lin et al., 2003). In addition to
numerous other pathways, EGCG has been demonstrated to inhibit
fatty acid synthesis (Wang and Tian, 2001; Brusselmans et al., 2003)
through its effect on the regulation of acetyl-CoA carboxylase (ACC)
(Huang et al., 2009). ACC catalyzes the ﬁrst committed step in fatty
acid synthesis: the ATP-dependent carboxylation of acetyl-CoA,
which provides the two-carbon donor, malonyl-CoA, for fatty acid
synthesis (Tong and Harwood, 2006). ACC is negatively regulated
by phosphorylation by AMP-activated protein kinase (AMPK), aess under CC BY-NC-ND license.
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Brownsey et al., 2006). EGCG treatment activates AMPK, leading
to increased phosphorylation of human ACC, which resulted in its
inhibition (Moon et al., 2007; Huang et al., 2009).
In T. b. brucei, both the cytoplasmic and mitochondrial fatty acid
synthesis pathways are important for growth in culture and viru-
lence in mouse models (Lee et al., 2006, 2007; Stephens et al.,
2007; Vigueira and Paul, 2011). We have recently demonstrated
that RNA interference (RNAi)-mediated gene knock-down of ACC
in T. b. brucei reduced fatty acid elongation activity in intact cells
and reduced virulence in a mouse model of infection (Vigueira
and Paul, 2011). In addition, treatment with thiolactomycin, an
inhibitor of fatty acid synthetase, inhibited fatty acid synthesis
activity and growth of T. b. brucei in culture (Morita et al., 2000).
Taken together, these results suggest that fatty acid synthesis has
the potential to be an effective drug target in T. brucei. Here, we
examined the effect of EGCG on T. b. brucei and found that physio-
logically relevant levels of EGCG had no effect on growth in culture
and did not reduce virulence in a mouse model of infection, while
higher levels of EGCG decreased TbACC activity, likely through an
increase in TbACC phosphorylation. These data suggest that
although EGCG inhibits T. b. brucei ACC activity, EGCG is a ques-
tionable candidate for further development as a potential cure
for T. brucei infection. However, EGCG may be a useful pharmaco-
logical tool to investigate the signaling pathways governing phos-
pho-regulation of TbACC.2. Material and methods
2.1. Materials, cell lines, and media
Most chemicals and reagents were purchased from Thermo
Fisher Scientiﬁc and Sigma, including EGCG (E4143), which was
prepared and frozen in single-use aliquots, either as a 100X stock
in dimethyl sulfoxide (DMSO) or in sterile water for use in mice.
EGCG stocks were freshly thawed just before use. Minimum essen-
tial medium and Iscove’s modiﬁed Dulbecco’s medium, was from
Invitrogen. Serum Plus was from JRH Biosciences. [14C]NaHCO3
(14.9 mCi mmol1) was from American Radiolabeled Chemicals.
Wild-type (WT) T. b. brucei 427 bloodstream form (BF) and tsetse
midgut procyclic form (PF) cell lines were a kind gift of Dr. Paul
Englund (Johns Hopkins School of Medicine). BFs were grown at
37C/5% CO2 in HMI-9 media containing 10% heat-inactivated fetal
bovine serum (FBS) and 10% Serum Plus (Hirumi and Hirumi,
1989). PFs were grown at 28C/5% CO2 in SDM-79 media contain-
ing 10% heat-inactivated FBS and 7.5 lg ml1 hemin (Brun and
Shonenberger, 1979). PF ACC-myc cells are tagged in one genomic
locus with a c-terminal fusion to the c-myc epitope and have been
described previously (Vigueira and Paul, 2011). BF ACC-myc cells
were generated in this study with the same tagging construct used
to make the PF ACC-myc cell line. ACC-myc cell lines are main-
tained in the appropriate growth media supplemented with
2.5 lg ml1 phleomycin.2.2. Effect of EGCG on T. b. brucei growth
WT BF T. b. brucei were diluted into fresh media containing 0.1–
1 lM EGCG or 1% DMSO as the solvent control and the cell culture
densities measured every 2 days for 6 days by ﬂow cytometry (BD
FACScan). Following each cell count, cultures were diluted to main-
tain logarithmic phase growth, and EGCG/DMSO was added to
maintain experimental concentrations. Doubling times were calcu-
lated from the growth curves. To determine EC50 for growth, WT BF
and PF T. brucei were diluted into fresh media containing 5–50 lMEGCG or 1% DMSO as solvent control and cell culture densities
determined after 2 days.
2.3. ACC activity assays
Hypotonic lysates were desalted and TbACC activity was as-
sayed essentially as described (Vigueira and Paul, 2011). Brieﬂy,
ACC activity was determined by measuring the incorporation of
the [14C]CO2 from [14C]NaHCO3 into the acid resistant [14C]malo-
nyl-CoA product, which is quantiﬁed by scintillation counting. To
test the effect of EGCG on TbACC activity, 5-100 lM EGCG or 1%
DMSO only (solvent control) was added to the lysates with or with-
out 1X HALT phosphatase inhibitor cocktail (Thermo Scientiﬁc
Pierce) just prior to assaying for TbACC activity.
2.4. ACC phosphorylation and blotting
Hypotonic lysates from BF and PF ACC-myc cells were prepared
in the presence of 1X HALT phosphatase inhibitor cocktail. Lysates
were supplemented with 5 mM ATP, divided, with one aliquot
treated with 100 lM EGCG and the other with 1% DMSO as solvent
control. Lysates were then incubated at 30 C for 30 min. under
constant mixing (Eppendorf Thermomixer, 500 rpm). ACC-myc
was immunoprecipitated from the lysates using the ProFound
c-myc IP/Co-IP kit (Thermo Scientiﬁc Pierce) according to the man-
ufacturer’s instructions and eluted in 150 mM glycine at pH 2.2
followed by immediate neutralization with 9.5 M Tris–HCl, pH 9.0.
To detect phosphorylated ACC-myc, approximately equal quan-
tities of immunoprecipitated ACC-myc (8.8  107 cell equiva-
lents/lane for PF and 1.5  108 cell equivalents/lane for BF) were
resolved by SDS–10% PAGE, followed by gel staining with Pro Dia-
mond Q phosphoprotein gel stain (Invitrogen) according to the
manufacturer’s instructions. Phospho-stained gels were imaged
under UV using the Gel Doc XR Imaging System (BioRad). To detect
total ACC, identically loaded non-stained gels were transferred to
nitrocellulose and probed for ACC as described (Vigueira and Paul,
2011) with streptavidin conjugated to horseradish peroxidase
(SA-HRP), which detects the ACC biotin prosthetic group. Densito-
metric quantitation was performed on gels and appropriately ex-
posed blots (in the linear range of detection) using Image J
software (NIH). Phosphorylated ACC-mycwas normalized to the to-
tal amount of ACC in the ACC-myc immunoprecipitates and lysates.
2.5. Mouse infection
To test the ability of EGCG to clear a T. b. brucei infection in
mice, we chose a daily dose of 4.13 mg/kg EGCG prepared in sterile
H2O and administered daily by IP injection. This EGCG concentra-
tion had been previously determined not to cause mouse liver
damage, though actual serum levels of EGCG were not determined
(Güida et al., 2007). For the EGCG-treated group, 12 week old Swiss
mice were pre-treated with EGCG for 2 days prior to infection and
EGCG treatment was continued throughout the course of infection.
Both the EGCG-treated (n = 5) and untreated controls (n = 5) were
infected with 1  105 BF wild-type 427 parasites as previously de-
scribed (Bacchi et al., 2009). Tail blood samples were examined by
microscopy to conﬁrm successful infection, and time to death (or
humane end-point) was determined. All work with animals was
carried out in compliance with a protocol approved by the Clemson
University Institutional Animal Care and Use Committee.3. Results and discussion
To investigate whether EGCG could be used to target ACC in T. b.
brucei, we ﬁrst tested EGCG for its ability to inhibit TbACC
P.A. Vigueira et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 225–229 227enzymatic activity in whole cell lysates from two different life cy-
cle stages: the procyclic form (PF) found in the ﬂy midgut, and the
mammalian bloodstream form (BF). Because of the known mode of
action of EGCG on mammalian ACC phosphorylation, we sought to
preserve any potential changes in phosphorylation caused by EGCG
by adding HALT, a broad-spectrum phosphatase inhibitor, to the
cell lysate. In the presence of HALT, EGCG reduced ACC activity
in both BF and PF lysates, with an EC50 of 29 ± 1.3 lM (n = 3) and
55 ± 2.4 lM (n = 3), respectively (Fig. 1A and B). HALT treatment
alone had no effect on ACC activity (data not shown). However,
in the absence of HALT, we observed no inhibition of TbACC activ-
ity in lysates by EGCG. Thus, EGCG treatment inhibited ACC activity
only in the presence of phosphatase inhibitors. Although the effect
of EGCG on ACC activity in lysates has not been previously mea-
sured, our observations are consistent with the reported mode of
action of EGCG on ACC by increasing ACC phosphorylation (Collins
et al., 2007; Hwang et al., 2007; Moon et al., 2007; Huang et al.,
2009; Murase et al., 2009). That no effect was observed in the ab-
sence of HALT rules out a more general inhibitory ‘‘tannin’’ effect
on the ACC enzyme (Wink, 2008). Thus, we propose that HALT,
by inhibiting the endogenous phosphatases in the lysate, preserved
an EGCG-driven increase in ACC phosphorylation, resulting in de-
creased TbACC activity.
To more directly examine the effect of EGCG treatment on
TbACC phosphorylation, we used BF and PF cell lines in which
the C-terminus of one TbACC allele was fused to the c-myc epitope
(TbACC-myc), which allows for expression of TbACC-myc at endog-Fig. 1. Inhibition of TbACC activity by EGCG. TbACC activity in lysates of (A) BF and
(B) PF trypanosomes was measured in the presence of 5–100 lM EGCG in the
absence (black bars) or presence (grey bars) of HALT phosphatase inhibitor cocktail.
As a negative control, ATP was omitted from the reaction (No ATP). Values are
expressed as a percentage of the DMSO solvent control. DMSO concentrations were
maintained at 1% v/v for all conditions. The mean of 3 independent experiments is
shown. Error bars indicate ±SEM. The * indicates P < 0.01 for the difference between
DMSO control and EGCG-treated conditions (student’s t-test).
Fig. 2. EGCG induces phosphorylation of TbACC. BF and PF ACC-myc lysates were
treated with 100 lM EGCG or DMSO as solvent control in the presence of HALT
phosphatase inhbitor cocktail. (A) BF and (B) PF TbACC-myc immunoprecipitates
(5  108 cell equivalents/lane) were resolved by SDS–PAGE and stained with Pro Q
Diamond phosphoprotein gel stain to detect phosphorylated ACC (ACC-p; upper
panels). Identically loaded gels were blotted to nitrocellulose and probed for total
ACC with SA-HRP (ACC-t; bottom panels). Representative gels and blots are shown.
Unlabeled upper band in panel A is an unknown phosphorylated contaminant.
(C) Densitometric quantitation of phosphorylated ACC from phospho-stained gels
normalized to total ACC detected by SA-HRP blotting. The mean of 3 independent
experiments is shown. Error bars indicate the ±SEM. The * indicates P < 0.05 and
** indicates P < 0.00001 for the difference between DMSO control and EGCG-treated
conditions (student’s t-test).enous levels under the native promoter (Vigueira and Paul, 2011;
and this study). BF and PF TbACC-myc lysates were treated with
100 lM EGCG or DMSO as solvent control in the presence of HALT.
After EGCG treatment, TbACC-myc immunoprecipitates were re-
solved by SDS–PAGE and phosphorylated TbACC detected by in-
gel phospho-staining with Pro Q Diamond stain (Fig. 2A and B,
upper panels, respectively). As a loading control, identically-loaded
gels were transferred to nitrocellulose and total ACC detected by
blotting with streptavidin-HRP (Fig. 2A and B, lower panels).
Densitometry of the phospho-stained gels revealed that EGCG
treatment resulted in a statistically signiﬁcant 4.7 ± 0.12-fold
(P < 0.00001; n = 3) and 1.7 ± 0.20-fold (P < 0.05; n = 3) increase in
phosphorylation of TbACC in BFs and PFs, respectively. This in-
crease in phosphorylation is correlated with the observed inhibi-
tion of TbACC activity in BF and PF lysates (Fig. 1A and 1B). It is
possible that ACC-myc is inefﬁciently or aberrantly phosphorylated
compared to native ACC, which might mask the true response of
ACC to EGCG treatment. However, the facts that immunoprecipi-
tated ACC-myc was also highly active and ACC-myc exhibited the
same subcellular fractionation as native ACC (Vigueira and Paul,
2011) argue against this idea. In addition, similar increases in
ACC phosphorylation were observed in mammalian cells after
treatment with similar concentrations of EGCG (50–400 lM)
(Hwang et al., 2007; Moon et al., 2007; Huang et al., 2009; Murase
et al., 2009). Taken together, the results shown in Figs. 1 and 2
Fig. 3. Effect of EGCG on in vitro growth of T. brucei. (A and B) WT BF cells were diluted back to 1  106 cells/ml into fresh media containing 0.1–1 lM EGCG or DMSO as the
solvent control and culture cell densities were monitored for 6 days. (A) Representative growth curve showing cumulative culture densities. (B) Mean culture doubling times
of 3 independent experiments. Error bars show ±SEM. (C) WT BF and (D) WT PF cells were back-diluted into fresh media containing 5–50 lM EGCG or DMSO control. Culture
cell densities were determined after 48 h. Values are expressed as a percentage of DMSO control. The mean of 4 independent experiments is shown. Error bars show ±SEM.
The * indicates P < 0.01 for the difference between DMSO and EGCG-treated conditions (student’s t-test).
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and that EGCG treatment leads to increased TbACC phosphoryla-
tion and correspondingly decreased TbACC activity. It is unknown
how EGCG treatment leads to phosphorylation and inactivation of
TbACC. In mammalian cells, how EGCG activates AMPK is not well
understood, but occurs via activation of one or more upstream ki-
nases (e.g. liver kinase B1 (LKB1) and calmodulin-dependent pro-
tein kinase kinase (CaMKK)) in a process that may involve the
production of reactive oxygen species (ROS) via oxidation of EGCG
(Sang et al., 2005; Hou et al., 2005; Hwang et al., 2007; Collins
et al., 2007; Moon et al., 2007; Murase et al., 2009). Future work
will be needed to determine the identity of the upstream TbACC
kinase(s) and the role of ROS in their signaling.
We next examined the effect of EGCG on T. b. brucei growth in
culture. Orally administered EGCG is rapidly cleared from the body
(Ullmann et al., 2003; Chow et al., 2005). In humans, repeated daily
oral administration of EGCG can achieve a maximum plasma con-
centration of 1 lM for 5–6 h (Ullmann et al., 2004). A 6 day treat-
ment of BF cells at these physiological EGCG concentrations (0.1–
1 lM) caused no change in growth or doubling time (Fig. 3A and
B). Next, we tested higher EGCG concentrations (5–50 lM), and ob-
served a statistically signiﬁcant reduction in cell growth over 48 h
(Fig. 3C and D), with an EC50 of 34 ± 2.4 lM and 25 ± 2.7 lM for BF
and PF parasites, respectively (P < 0.01, n = 4). These values are
consistent with the trypanocidal activity of EGCG (IC50 20.2 lM
at 72 h) previously reported for T. b. rhodesiense (Tasdemir et al.,
2006). Our previous data showed that TbACC is largely unneces-
sary in BF parasites cultured in vitro and is only required when
PF parasites are cultured in low-lipid media (Vigueira and Paul,
2011). Thus, we contend that inhibition of TbACC by EGCG should
have little consequence on T. b. brucei growth in culture. Conse-
quently, we attribute the reduction in growth observed with EGCG
concentrations >5 lM to other previously described target(s) ofEGCG (Ahmed, 2010; Singh et al., 2011), rather than to its inhibi-
tion of TbACC.
Finally, we examined the effect of EGCG treatment on the
course of T. b. brucei infection in mice. Although the EC50 values
for EGCG for growth in culture are greater than the achievable
physiological concentrations in humans, there were three reasons
to justify testing EGCG in a mouse model of infection. First, T. b.
brucei exhibited condition-speciﬁc essentiality in the case of both
TbACC and enoyl-CoA reductase (EnCAR). PF ACC and EnCAR RNAi
cell lines exhibited slowed growth only when exogenous lipids
were limited, and a TbACC RNAi line had attenuated virulence in
mice (Lee et al., 2006; Vigueira and Paul, 2011). Second, studies
in rats showed that intravenous administration of EGCG resulted
in greater plasma half-life and in higher maximal plasma concen-
trations than seen with the oral route of administration (Isbrucker
et al., 2006; Misaka et al., 2012). Third, previous studies of EGCG in
mice have yielded promising results for treatment of trypanosomi-
asis. T. cruzi mortality in mice and growth in culture was reduced
with EGCG treatment (Paveto et al., 2004; Güida et al., 2007). In
addition, inﬂammation caused by T. b. brucei infection was reduced
and survivorship was extended with oral green tea supplementa-
tion (Karori et al., 2008). Taken together, these observations sug-
gest that ﬁrst, parenteral administration of EGCG might achieve
therapeutic plasma concentration of EGCG, and second, the
requirement for ACC and thus the parasite’s sensitivity to EGCG
could be higher in vivo.
To test the ability of EGCG to clear a T. b. brucei infection in
mice, we administered daily IP injections of 4.13 mg/kg EGCG in
sterile H2O two days prior to infection and over the course of the
trial. This EGCG concentration had been previously determined
not to cause mouse liver damage, though the actual EGCG serum
concentration was not determined (Güida et al., 2007). After 2 days
of EGCG pre-treatment, Swiss mice were then infected with
P.A. Vigueira et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 225–229 2291  105 BF wild-type 427 parasites as previously described (Bacchi
et al., 2009), and time until death (or humane end-point) was
determined. In this infection model, EGCG treatment had no effect
on infection duration or mouse mortality. Mean time until death
was 3.5 days for both treatment and control groups (data not
shown). Thus, although EGCG has trypanocidal activity at supra-
physiological concentrations, the compound did not attenuate vir-
ulence in our acute infection mouse model. EGCG concentrations
may not have been sufﬁciently high in the mouse bloodstream to
affect the parasite, however a much lower intraperitoneal dose
(0.8 mg/kg/day) led to a signiﬁcant decrease in parasitemia and in-
creased survivorship of mice infected with T. cruzi (Güida et al.,
2007). Alternatively, it is possible that the course of infection
was too rapid to allow EGCG to exert its effects. If so, a chronic
infection model might be better suited to examine the efﬁcacy of
EGCG as a possible anti-trypanosomiasis therapy.
In summary, we found that EGCG inhibits TbACC activity in ly-
sates, and this inhibition was correlated with an increase in ACC
phosphorylation. This suggests that EGCG may be a useful tool
for studying the effects of phosphorylation on TbACC activity. We
also demonstrated that EGCG kills both PF and BF parasites in cul-
ture. However, EGCG treatment did not affect T. b. brucei virulence
in a mouse model of acute infection, which reduces its promise as a
therapeutic candidate to treat T. brucei infection.
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